Search | IOVS | ARVO Journals

Showing 1 – 20 of 50

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

NT-501 Secreted Protein Characterization Using Mass Spectroscopy and Cytokine/Chemokine Multiplex Array

Eugene Gonzalez-Lopez; Sid Plakkot; Arne Nystuen; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3954.

ARVO Annual Meeting Abstract June 2024

Immunogenicity Analysis of the NT-501 Intraocular Implant on a Cohort of Study Participants

Arne Nystuen; Matthew Fera; Sid Plakkot; Konrad Kauper; Thomas Aaberg

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3949.

ARVO Annual Meeting Abstract June 2024

Hydrolytic Stability and Seal Integrity Evaluation of the NT-501 Capsule and Capsule Component Materials

Lovisa Selander; Preston Lanier; Konrad Kauper; Eugene Gonzalez-Lopez

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3166.

ARVO Annual Meeting Abstract June 2023

Development of a NT-501 In-Vitro Sampling Procedure Replicating Implant In-Vivo CNTF Secretion Levels

Preston Lanier; Lovisa Selander; Konrad Kauper; Lisa Orecchio; Eugene Gonzalez-Lopez

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3683.

ARVO Annual Meeting Abstract June 2023

Continuous Intraocular Drug Delivery Lasting Over a Decade: Ciliary Neurotrophic Factor (CNTF) Secreted from Neurotech's NT-501 Implanted in Subjects with Retinal Degenerative Disorders

Konrad Kauper; Lisa Orecchio; Arne Nystuen; Kayla Medeiros; Alice Lee; Vanessa Cavallaro; Jacque L Duncan; Thomas Aaberg

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3680.

ARVO Annual Meeting Abstract June 2023

Development and justification of a HPLC-MS method to establish the integrity of Neurotech’s intraocular implant (NT-501 Implant)

Lovisa Selander; Preston Lanier; Konrad Kauper; Eugene Gonzalez-Lopez

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3670.

ARVO Annual Meeting Abstract June 2023

Maintenance of CNTF secreting vector in genetically engineered ARPE-19 cells over clinical cell scale up

Sid Plakkot; Matthew Fera; Arne Nystuen; Crystal Cortellessa; Sandy Sherman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3662.

ARVO Annual Meeting Abstract June 2015

Analysis of Binding Affinity and Inhibitory Capacity of NT-503 Produced VEGF Antagonist Compared to Aflibercept

Michael Rivera; Arne Nystuen; Konrad Kauper; Alline M. A. Lelis; Lisa D. Orecchio; Sue Elliott; Paul Stabila

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):228.

ARVO Annual Meeting Abstract June 2015

Proteomic Mass Spectroscopy Profiling of Proteins Secreted from an Encapsulated Cell Technology (ECT) Implant Device

Lisa D. Orecchio; Michael Rivera; Edward Brissette; Cahil McGovern; Arne Nystuen; Rhett Schiffman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):229.

ARVO Annual Meeting Abstract June 2015

Evaluation of Retinal Structure and Function of Rabbits Following Continuous VEGF Inhibition by Encapsulated Cell Therapy (ECT)

Alline M. A. Lelis; Michael Rivera; Lisa D. Orecchio; Pam Heatherton; Edward Brissette; Alice Lee; Cahil McGovern; Arne Nystuen; Rhett M Schiffman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):232.

ARVO Annual Meeting Abstract April 2014

Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist

Konrad Kauper; Michael Rivera; John Mills; Alline Lelis; Megan Billings; Cahil McGovern; Arne Nystuen; Sandy Sherman; Pam Heatherton; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):441.

ARVO Annual Meeting Abstract June 2013

Generation of Combination PDGF / VEGF-antagonist ECT devices

Vincent Ling; Arne Nystuen; Susan Elliott; Lisa Orecchio; Brenda Dean; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3290.

ARVO Annual Meeting Abstract June 2013

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Cahil McGovern; John Duggan; Crystal Cortellessa; Sandy Sherman; Melissa Stiles; Konrad Kauper; Allyse Mazzarelli; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3294.

ARVO Annual Meeting Abstract June 2013

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Konrad Kauper; Cahil McGovern; Paul Stabila; Sandy Sherman; Pam Heatherton; Brenda Dean; Crystal Cortellessa; Alice Lee; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3295.

ARVO Annual Meeting Abstract June 2013

Intraocular Delivery of Ciliary Neurotrophic Factor (CNTF) by Encapsulated Cell Technology Implants Restores Cone Function and Day Vision in Dogs with CNGB3 -Achromatopsia

Andras Komaromy; Kristin Koehl; Christine Harman; Pam Heatherton; Konrad Kauper; Gustavo Aguirre; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1718.

Clinical and Epidemiologic Research November 2012

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

PDF

Konrad Kauper; Cahil McGovern; Sandy Sherman; Pam Heatherton; Rob Rapoza; Paul Stabila; Brenda Dean; Alice Lee; Suzanna Borges; Bruce Bouchard; Weng Tao
TAGS: ciliary neurotrophic factor, implants, degenerative disorders
Invest. Ophthalmol. Vis. Sci.. 2012; 53(12):7484-7491. https://doi.org/10.1167/iovs.12-9970

ARVO Annual Meeting Abstract March 2012

Development of an Optimized Culture Media to Improve VEGF Antagonist Secretion and Stability by Encapsulated Cell Technology Implants

Alline M. Lelis; Michael Rivera; Sue Elliott; Brenda Dean; Pam Heatherton; Bruce Bouchard; Melissa Stiles; Vicent Ling; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):454.

ARVO Annual Meeting Abstract March 2012

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Konrad Kauper; Vincent Ling; Sue Elliot; Cahil McGovern; Sandy Sherman; Brenda Dean; Lisa Orecchio; Mike Rivera; Pam Heatherton; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):455.

ARVO Annual Meeting Abstract March 2012

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Cahil McGovern; Sandy Sherman; Crystal Cortellessa; Suzanna Borges; Melissa Stiles; Karen Ahola; Alice Lee; Konrad Kauper; Bruce Bouchard; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):465.

ARVO Annual Meeting Abstract March 2012

Pharmacokinetics of a VEGF Antagonist Delivered by an Intraocular Encapsulated Cell Technology Implant

Michael Rivera; Alline Lelis; Bruce Bouchard; Melissa Stiles; Vincent Ling; Konrad Kauper; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):474.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

NT-501 Secreted Protein Characterization Using Mass Spectroscopy and Cytokine/Chemokine Multiplex Array

Immunogenicity Analysis of the NT-501 Intraocular Implant on a Cohort of Study Participants

Hydrolytic Stability and Seal Integrity Evaluation of the NT-501 Capsule and Capsule Component Materials

Development of a NT-501 In-Vitro Sampling Procedure Replicating Implant In-Vivo CNTF Secretion Levels

Continuous Intraocular Drug Delivery Lasting Over a Decade: Ciliary Neurotrophic Factor (CNTF) Secreted from Neurotech's NT-501 Implanted in Subjects with Retinal Degenerative Disorders

Development and justification of a HPLC-MS method to establish the integrity of Neurotech’s intraocular implant (NT-501 Implant)

Maintenance of CNTF secreting vector in genetically engineered ARPE-19 cells over clinical cell scale up

Analysis of Binding Affinity and Inhibitory Capacity of NT-503 Produced VEGF Antagonist Compared to Aflibercept

Proteomic Mass Spectroscopy Profiling of Proteins Secreted from an Encapsulated Cell Technology (ECT) Implant Device

Evaluation of Retinal Structure and Function of Rabbits Following Continuous VEGF Inhibition by Encapsulated Cell Therapy (ECT)

Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist

Generation of Combination PDGF / VEGF-antagonist ECT devices

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Intraocular Delivery of Ciliary Neurotrophic Factor (CNTF) by Encapsulated Cell Technology Implants Restores Cone Function and Day Vision in Dogs with CNGB3 -Achromatopsia

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

Development of an Optimized Culture Media to Improve VEGF Antagonist Secretion and Stability by Encapsulated Cell Technology Implants

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Pharmacokinetics of a VEGF Antagonist Delivered by an Intraocular Encapsulated Cell Technology Implant

To View More...

You must be signed into an individual account to use this feature.